Sun Pharma Q1 Results FY2023, PAT at Rs. 20609 million

Sun Pharma Q1 Results FY2023

Corporate Action
by Shreya Anaokar Last Updated: 2022-08-01T18:15:51+05:30

On 30th July 2022, Sun Pharma announced its quarterly results for the first quarter of FY2023.

Key Highlights:

- Gross sales at Rs. 107,617 million, a growth of 10.73% 

- EBITDA at Rs. 28,844 million (including other operating revenues), with EBITDA margin at 26.8% 

- Net profit for the quarter was at Rs. 20,609 million, up by 42.7% YoY. Excluding the exceptional items of Q1 last year, adjusted net profit was up by 4.1%. 


Business Highlights:

- Sales of formulations in India for Q1FY23 were at 33,871 million, up 13% on like-to-like basis, excluding Covid product sales of Q1 last year. On a reported basis, the growth is 2.4% over Q1 last year. India formulation sales accounted for about 32% of total consolidated sales.

- Formulation sales in the US were US$ 420 million recording a growth of 10.7% over Q1 last year; accounting for over 30% of total consolidated sales.

- Taro posted Q1FY23 sales of US$ 157 million and a net profit of US$ 14 million. Taro’s financials include the first full quarter of consolidation of the Alchemee acquisition. 

- The sales in Emerging Markets were at US$ 245 million for Q1, a growth of 12.6% over Q1 last year. Overall sales in Emerging Markets accounted for about 18% of total consolidated sales for the quarter.

- Formulation sales in Rest of World (ROW) markets, excluding US and Emerging Markets, were US$ 190 million in Q1FY23, up by 2.6% over Q1 last year and accounted for approximately 14% of total consolidated sales.  

- For Q1FY23, external sales of API were at Rs. 5,987 million, up by 16.3% over Q1 last year.


Commenting on the results, Dilip Shanghvi, Managing Director of the Company said, “For Q1, all our businesses recorded good growth, driven by a combination of sustained scale-up for our specialty business and all-round growth across markets. The specialty business has grown by 29% driven by Ilumya, Cequa, Odomzo, and Winlevi. Our India business continues to grow faster than the market, leading to an increase in market share. We have been able to report healthy margins despite rising costs. We continue to focus on expanding our global specialty business, growing all our businesses, and improving our market share.”


Start Investing in 5 mins*

Get Benefits worth 2100* | Rs. 20 Flat Per Order | 0% Brokerage

About the Author

Shreya Anaokar is a Content Writer at 5paisa. She has completed her Master’s in Finance and Graduation in Statistics from the University of Mumbai. 


Investment/Trading is subject to market risk, past performance doesn’t guarantee future performance. The risk of trading/investment loss in securities markets can be substantial. Also, the above report is compiled from data available on public platforms.

Open Free Demat Account

& get benefits worth 2100*

Resend OTP
Please Enter OTP
  • Have Promo code?
  • Use code ACT2100
Enter Promo code
Account belongs to

By proceeding, you agree to the T&C.

Start Investing Now!

Open Free Demat Account in 5 mins

Enter Valid Mobile Number